News

Back

Stealth BioTherapeutics to Host KOL Breakfast Symposium on the Potential of Elamipretide in Orphan Mitochondrial Disorders

July 02, 2019

BOSTON, July 2, 2019 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that the Company will host a key opinion leader (KOL) breakfast symposium on Thursday, July 11, 2019 at 8:00 a.m. ET in New York City. The event will focus on the potential of the Company's lead candidate, elamipretide, in Primary Mitochondrial Myopathy and Barth's Syndrome and showcase data from its ongoing clinical programs, including data which was recently presented at Mitochondrial Medicine Symposium 2019, posters from which are now available on the Company's website.

Stealth BioTherapeutics Logo (PRNewsfoto/Stealth BioTherapeutics)

A live audio webcast of the event will be available on the Investors & News section of Stealth's website at https://investor.stealthbt.com/. A replay of the webcast will be archived on Stealth's website for 30 days following the event.

About Stealth

We are a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body's main source of energy production and are critical for normal organ function. Dysfunctional mitochondria characterize a number of rare genetic diseases, collectively known as primary mitochondrial diseases, and are also involved in many common age-related diseases. We believe our lead product candidate, elamipretide, has the potential to treat both rare genetic and common age-related mitochondrial diseases. We are studying elamipretide in the following primary mitochondrial diseases: primary mitochondrial myopathy, Barth syndrome and Leber's hereditary optic neuropathy. We are also studying elamipretide in dry age-related macular degeneration. Our other pipeline candidates include SBT-272, which we are evaluating for rare neurodegenerative disease indications, and SBT-20, which we are evaluating for rare peripheral neuropathies. We have optimized our discovery platform to identify novel mitochondrial-targeted compounds, which may be nominated as therapeutic product candidates or utilized as scaffolds to deliver other compounds to mitochondria. We have assembled a highly experienced management team, board of directors and group of scientific advisors to help us achieve our mission of leading mitochondrial medicine.

Media Relations
dna Communications
Kate Contreras, 617-520-7088
Media@StealthBT.com 

Investor Relations
Stern Investor Relations
Lauren Stival, 212-362-1200
IR@StealthBT.com 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/stealth-biotherapeutics-to-host-kol-breakfast-symposium-on-the-potential-of-elamipretide-in-orphan-mitochondrial-disorders-300878918.html

SOURCE Stealth BioTherapeutics

Media Relations

dna Communications
Kate Contreras, 617-520-7088
media@stealthbt.com

Investor Inquiries
Stern IR
Lauren Stival, 212-362-1200
IR@stealthbt.com